Rice Harbut Elliott LLP is investigating a possible class action lawsuit on behalf of persons who ingested medication sold in B.C. and Quebec which may pose serious health risks, after Health Canada became aware of an impurity, N-nitrosodimethylamine (NDMA), which has been detected in some drugs. NDMA is classified as a probable human carcinogen, which means long-term exposure to levels above what is considered safe could increase the risk of cancer.
There has recently been a voluntary recall of the following over the counter medications:
|Company||Product Name/Active Pharmaceutical Ingredient (API)||DIN||Strength||Lot||Date added|
|Apotex Inc.||Acid Reducer (ranitidine) sold under the brand names Equate and Selection||02296160||150 mg||All lots||September 25, 2019|
|Apotex Inc.||Apo-Ranitidine Oral Solution||02280833||15 mg/mL||All lots||September 25, 2019|
|Apotex Inc.||Apo-Ranitidine Tablet 150mg||00733059||150 mg||All lots||September 25, 2019|
|Apotex Inc.||Apo-Ranitidine Tablet 300mg||00733067||300 mg||All lots||September 25, 2019|
|Pro Doc Limitée||Ranitidine – 150||00740748||150 mg||All lots||September 25, 2019|
|Pro Doc Limitée||Ranitidine – 300||00740756||300 mg||All lots||September 25, 2019|
|Sandoz Canada||Sandoz Ranitidine||02243229||150 mg||All lots||September 17, 2019|
|Sandoz Canada||Sandoz Ranitidine||02243230||300 mg||All lots||September 17, 2019|
|Sanis Health Inc.||Ranitidine||02353016||150 mg||All lots||September 25, 2019|
|Sanis Health Inc.||Ranitidine||02353024||300 mg||All lots||September 25, 2019|
|Sivem Pharmaceuticals ULC||Ranitidine||02385953||150 mg||NP4179
|September 25, 2019|
|Sivem Pharmaceuticals ULC||Ranitidine||02385961||300 mg||NP4177
|September 25, 2019|
The Health Canada recall can be found here.
If you have purchased any affected products as listed above we would be interested in hearing from you. Joining our contact list creates no financial obligation and we will keep all the information that you provide to us confidential.
Note: You are not obliged to fill in this form to participate in this class action. If you choose to do so, you are not retaining RHE LLP to act on your behalf. Providing the information requested does not make you a client of RHE LLP. All information submitted will be treated as confidential and will only be released as required by law or as you may consent.
I provide my consent and agree herein to receive communications from RHE LLP, which may include announcements regarding class actions, practice updates, newsletters, publications, event invitations or other information that may be of interest. I understand that consent to receive these electronic communications may be withdrawn at any time by emailing email@example.com.